Effect of Oral Calcium Butyrate Supplementation in Obesity

People with obesity tend to have an imbalanced gut microbiome that produces less butyrate — a beneficial fatty acid made when gut bacteria ferment dietary fiber. Lower butyrate levels are thought to weaken the gut's protective lining, allowing bacterial fragments to leak into the bloodstream and trigger chronic, low-grade inflammation. This trial, planned at a major Mexican nutrition research institute, will test whether giving people with obesity a daily oral calcium butyrate supplement can reverse some of those effects. Specifically, researchers want to know whether supplementation improves the health of immune cells called monocytes — particularly how well their mitochondria (the cell's energy generators) function — and whether it shifts the gut microbiome toward a healthier balance. The study is a rigorous randomized, double-blind, placebo-controlled design, meaning neither participants nor investigators will know who receives the active supplement. Because it is not yet recruiting as of mid-2026, no results are available; the entry here documents the trial's rationale and design. If positive, the findings could support butyrate supplementation as a low-cost, accessible strategy to reduce obesity-related inflammation by targeting the gut-immune-mitochondria axis.

• No results available — this trial is registered but not yet recruiting (status as of 2026-05-13); all findings listed here reflect the study's pre-specified hypotheses and design, not outcomes.
• The primary mechanistic hypothesis is that oral calcium butyrate (1000 mg/day, dose as reported in the registration) will improve mitochondrial bioenergetics in circulating monocytes in adults with obesity.
• Secondary hypotheses include improvements in intestinal barrier integrity markers and a favorable shift in gut microbiota composition, linking supplementation outcomes across mucosal, immune, and metabolic domains.

This is a randomized, double-blind, placebo-controlled trial being conducted at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico City). Participants are adults with obesity who will receive oral calcium butyrate at 1000 mg per day (as reported in the registration) versus matched placebo. Key outcome measures include monocyte mitochondrial function, systemic inflammatory markers, gut permeability indices, and gut microbiota profiling. Full sample size, randomization ratio, and follow-up duration are not specified in the available registration excerpt; confidence in methods detail is therefore low pending full protocol publication.

Because the trial has not yet recruited participants, no efficacy, safety, or mechanistic data exist; all inferences about outcomes would be premature. The oral delivery route raises an important unresolved question: calcium butyrate must survive gastric acid and reach the colon at biologically relevant concentrations, and the registration does not detail whether an enteric-coated formulation is used. The study population is limited to adults with obesity at a single Mexican tertiary-care center, which may limit generalizability to other ethnicities, BMI strata, or comorbidity profiles. A future experiment directly measuring luminal butyrate concentrations alongside systemic markers would help establish the pharmacokinetic bridge between supplementation dose and target-tissue effect.

This trial extends the mechanistic framework established by studies in this corpus linking gut microbial metabolites to mucosal and systemic immune outcomes. It parallels [§155], which examines how a microbial intervention (Saccharomyces boulardii) affects intestinal barrier function through overlapping epithelial-integrity pathways, and parallels [§156], which investigates Akkermansia muciniphila — a butyrate-sensitive commensal — in a metabolic-inflammatory condition, highlighting shared microbiome-modulation logic across different disease contexts. The trial also parallels [§149], where gut barrier disruption and microbial translocation are studied under physiological stress, reinforcing the concept that loss of barrier integrity is a convergent mechanism the present study aims to therapeutically reverse. More broadly, it sits within the corpus theme visible in [§150] — the role of gut microbiota in immune-related inflammatory diseases — by testing a targeted metabolite intervention rather than a whole-organism probiotic approach, which adds mechanistic granularity to the field.

• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Both test orally delivered gut interventions on intestinal barrier function endpoints, making them directly comparable on mechanism despite differing agents (probiotic yeast vs. butyrate salt).
• Role of Akkermansia Muciniphila in Acne Vulgaris
  Akkermansia muciniphila promotes colonocyte butyrate utilization; comparing this article with the present trial clarifies whether microbiome reconstitution or direct metabolite supplementation is the more efficient route to metabolic improvement in obesity.
• Combined heat and exercise stress disrupt gut microbiota and promote microbial translocation
  Examines gut barrier disruption and microbial translocation under stress conditions, providing a parallel model of the same leaky-gut mechanism the butyrate trial aims to therapeutically correct.
• Dietary Intervention with Brown Top Millet Starch Ameliorates Dyslipidaemia and Gut Leakiness in High Fat Diet Fed Models
  Dietary starch intervention targeting dyslipidaemia and gut leakiness in a high-fat diet model offers a dietary-fiber comparator — fiber fermentation is the endogenous source of butyrate — allowing readers to weigh exogenous supplementation against substrate-based strategies.
• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  This editorial synthesizes evidence on gut microbiota in immune-inflammatory disease, providing the conceptual framework within which the butyrate-monocyte-mitochondria hypothesis of the present trial should be interpreted.